

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33222> holds various files of this Leiden University dissertation

Author: Braak, Bas ter

Title: Carcinogenicity of insulin analogues

Issue Date: 2015-06-18

References

◀ IN THE PICTURE

Dark room with red light. This room was used to develop the light-sensitive Western blot films (in front of the picture). The exposed film was processed by immersing it in developing solution (container with black lid), fixed by thiosulfates (container with red lid) and cleaned with water. The films are only sensitive to blue/green light, thus red light enables the scientist to see what he is doing without exposing the film. Nowadays there are light sensitive imagers that can detect chemiluminescent light and immediately convert it to a digital image. This process might be quicker, but I prefer the old fashioned way.

◀ IN BEELD

Donkere kamer met rood licht. Deze kamer werd gebruikt om licht gevoelige Western blot films te ontwikkelen. De blootgestelde film werd verwerkt door hem onder te dompelen in ontwikkelingsoplossing (tank met zwarte dop), gefixeerd met tiosulfaten (tank met rode dop) en schoongemaakt met water. De films zijn alleen gevoelig voor blauw/groen licht. Met behulp van het rode licht kan de onderzoeker zien waarmee hij bezig is zonder de film bloot te stellen. Tegenwoordig worden ook wel lichtgevoelige scanners gebruikt voor de detectie van lichtgevoelige films. Deze scanners zijn een stuk sneller.

1. ICHS6(R1): **Preclinical safety evaluation of biotechnology-derived pharmaceuticals**. In.; 1997.
2. ICHS6(R1): **Addendum – preclinical safety evaluation of biotechnology-derived pharmaceuticals** In.; 2011.
3. Vahle JL, Finch GL, Heidel SM, Hovland DN, Jr., Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B *et al*: **Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations**. *Toxicol Pathol* 2010, **38**(4):522-553.
4. Van Oosterhout JP, Van der Laan JW, De Waal EJ, Olejniczak K, Hilgenfeld M, Schmidt V, Bass R: **The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe**. *Regulatory toxicology and pharmacology : RTP* 1997, **25**(1):6-17.
5. Friedrich A, Olejniczak K: **Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009)**. *Regulatory toxicology and pharmacology : RTP* 2011, **60**(2):225-248.
6. EMA: **Points to consider document on the non-clinical assessment of the carcinogenic potential of insulin analogues**, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC5000032_52.pdf. In.; 2002.
7. IARC: **breast cancer fact sheet**. 2012.
8. Peairs Ks Fau - Barone BB, Barone Bb Fau - Snyder CF, Snyder Cf Fau - Yeh H-C, Yeh Hc Fau - Stein KB, Stein Kb Fau - Derr RL, Derr Rl Fau - Brancati FL, Brancati Fl Fau - Wolff AC, Wolff Ac: **Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis**. (1527-7755 (Electronic)).
9. Larsson Sc Fau - Mantzoros CS, Mantzoros Cs Fau - Wolk A, Wolk A: **Diabetes mellitus and risk of breast cancer: a meta-analysis**. (0020-7136 (Print)).
10. Liao S Fau - Li J, Li J Fau - Wei W, Wei W Fau - Wang L, Wang L Fau - Zhang Y, Zhang Y Fau - Li J, Li J Fau - Wang C, Wang C Fau - Sun S, Sun S: **Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature**. (1513-7368 (Print)).
11. Xue F Fau - Michels KB, Michels KB: **Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence**. (0002-9165 (Print)).
12. Starup-Linde J, Karlstad O, Eriksen SA, Vestergaard P, Bronsveld HK, de Vries F, Andersen M, Auvinen A, Haukka J, Hjellvik V *et al*: **CARING (CAncer Risk and INSulin analogues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis**. *Curr Drug Saf* 2013, **8**(5):296-332.
13. De Bruijn KM, Arends Lr Fau - Hansen BE, Hansen Be Fau - Leeflang S, Leeflang S Fau - Ruiter R, Ruiter R Fau - van Eijck CHJ, van Eijck Ch: **Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer**. (1365-2168 (Electronic)).
14. Home P: **Insulin therapy and cancer**. *Diabetes Care* 2013, **36** Suppl 2:S240-244.
15. Pollak M, Russell-Jones D: **Insulin analogues and cancer risk: cause for concern or cause celebre?** *Int J Clin Pract* 2010, **64**(5):628-636.
16. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT: **Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study**. *Diabetologia* 2009, **52**(9):1732-1744.
17. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G: **Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden**. *Diabetologia* 2009, **52**(9):1745-1754.
18. Colhoun HM: **Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group**. *Diabetologia* 2009, **52**(9):1755-1765.
19. Currie CJ, Poole CD, Gale EA: **The influence of glucose-lowering therapies on cancer risk in type 2 diabetes**. *Diabetologia* 2009, **52**(9):1766-1777.
20. Butler PC: **Insulin glargine controversy: a tribute to the editorial team at Diabetologia**. *Diabetes* 2009, **58**(11):2427-2428.
21. Mollentze WF: **A possible link between insulin glargine and malignancy: the facts**. *Cardiovasc J Afr* 2009, **20**(4):216-218; discussion 218-219.
22. Werner H, Chantrelau EA: **Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years**. *Diabetology & Metabolic Syndrome* 2011, **3**.

23. Ciaraldi TP, Sasaoka T: **Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.** *Horm Metab Res* 2011, **43**(1):1-10.
24. Janghorbani M, Dehghani M, Salehi-Marzijarani M: **Systematic review and meta-analysis of insulin therapy and risk of cancer.** *Horm Cancer* 2012, **3**(4):137-146.
25. Karlstad O Fau - Starup-Linde J, Starup-Linde J Fau - Vestergaard P, Vestergaard P Fau - Hjellvik V, Hjellvik V Fau - Bazelier MT, Bazelier Mt Fau - Schmidt MK, Schmidt Mk Fau - Andersen M, Andersen M Fau - Auvinen A, Auvinen A Fau - Haukka J, Haukka J Fau - Furu K, Furu K Fau - de Vries F *et al*: **Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.** (2212-3911 (Electronic)).
26. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA: **Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies.** *Diabetes Metab* 2012, **38**(6):485-506.
27. Tang X, Yang L, He Z, Liu J: **Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.** *PLoS One* 2012, **7**(12):e51814.
28. Du X, Zhang R, Xue Y, Li D, Cai J, Zhou S, Huang Z, Yu R, Liu Y: **Insulin glargine and risk of cancer: a meta-analysis.** *The International journal of biological markers* 2012, **27**(3):e241-246.
29. PROSPERO: <http://www.crd.york.ac.uk/PROSPERO/>.
30. Moher D, Liberati A Fau - Tetzlaff J, Tetzlaff J Fau - Altman DG, Altman DG: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** (1549-1676 (Electronic)).
31. The Cochrane Collaboration. Higgins JPT GS, eds.: **Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011].** 2011.
32. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, Tennagels N, Werner U, LeRoith D: **Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.** *Diabetes* 2013, **62**(10):3553-3560.
33. Glendorf T, Knudsen L, Stidsen CE, Hansen BF, Hegelund AC, Sorensen AR, Nishimura E, Kjeldsen T: **Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues.** *PLoS One* 2012, **7**(2):e29198.
34. Hansen BF, Glendorf T, Hegelund AC, Lundby A, Lutzen A, Slaaby R, Stidsen CE: **Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.** *PLoS One* 2012, **7**(5):e34274.
35. Knudsen L, Hansen BF, Jensen P, Pedersen TA, Vestergaard K, Schaffer L, Blagoev B, Oleksiewicz MB, Kiselyov VV, De Meyts P: **Agonism and antagonism at the insulin receptor.** *PLoS One* 2012, **7**(12):e51972.
36. Liefvendahl E, Arnqvist HJ: **Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.** *Hormone and Metabolic Research* 2008, **40**(6):369-374.
37. Mayer D, Shukla A, Enzmann H: **Proliferative effects of insulin analogues on mammary epithelial cells.** *Arch Physiol Biochem* 2008, **114**(1):38-44.
38. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R: **ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor.** *Mol Carcinog* 1997, **18**(1):19-25.
39. Oleksiewicz MB, Bonnesen C, Hegelund AC, Lundby A, Holm GM, Jensen MB, Krabbe JS: **Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells.** *J Appl Toxicol* 2011, **31**(4):329-341.
40. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuille M, Tschank G, Tennagels N, Hampe C, Issad T: **Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2.** *PLoS One* 2012, **7**(7):e41992.
41. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R: **Biological Effects of Insulin and Its Analogs on Cancer Cells With Different Insulin Family Receptor Expression.** *J Cell Physiol* 2014.
42. Shukla A, Enzmann H, Mayer D: **Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells.** *Arch Physiol Biochem* 2009, **115**(3):119-126.
43. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D: **Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.** *Endocr Relat Cancer* 2009, **16**(2):429-441.
44. Staiger K, Hennige AM, Staiger H, Haering HU, Kellerer M: **Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells.** *Hormone and Metabolic Research* 2007, **39**(1):65-67.

45. Teng JA, Hou RL, Li DL, Yang RP, Qin J: **Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation.** *Horm Metab Res* 2011, **43**(8):519-523.
46. Ter Braak B, Siezen CL, Kannegieter N, Koedoot E, van de Water B, van der Laan JW: **Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.** *Arch Toxicol* 2014.
47. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H: **Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.** *Diabetes/metabolism research and reviews* 2009, **25**(1):41-49.
48. Gallagher EJ, Alikhani N, Tobin-Hess A, Cannata D, Tennagels N, Werner U, LeRoith D: **The effect of rhIGF-1 and insulin analogue AspB10 on mammary tumour growth and progression in a mouse model of type 2 diabetes.** *Diabetologia* 2012, **55**:S289.
49. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubaue H, Troschau G: **Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.** *International Journal of Toxicology* 2002, **21**(3):171-179.
50. Stammberger I, Essermeant L: **Insulin glargine: A reevaluation of rodent carcinogenicity findings.** *International Journal of Toxicology* 2012, **31**(2):137-142.
51. Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, Werner U: **Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats.** *Diabetologia* 2013, **56**(8):1826-1834.
52. ter Braak B, Siezen CL, Speksnijder E, Koedoot E, van Steeg H, Salvatori DCF, van de Water B, van der Laan JW: **Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model.** *Breast Cancer Research (accepted)* 2015.
53. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: **Long-term metformin use is associated with decreased risk of breast cancer.** *Diabetes Care* 2010, **33**(6):1304-1308.
54. Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Yu PC, Ryden LE, Pirags V, Spinaz GA, Birkeland KI *et al*: **The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia.** *Diabetes Care* 2014, **37**(5):1360-1366.
55. Carstensen B, Witte DR, Friis S: **Cancer occurrence in Danish diabetic patients: duration and insulin effects.** *Diabetologia* 2012, **55**(4):948-958.
56. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS: **Cancer risk associated with insulin Glargine among adult type 2 diabetes patients - a nationwide Cohort study.** *PLoS ONE* 2011, **6**(6).
57. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD: **The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project.** *Cancer Causes Control* 2012, **23**(7):1193-1203.
58. Dejgaard A, Lynggaard H, Rastam J, Krosgaard Thomsen M: **No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.** *Diabetologia* 2009, **52**(12):2507-2512.
59. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H: **Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases.** *Diabetes Care* 2013, **36**(2):294-301.
60. Ferrara A, Lewis JD, Quesenberry CP, Jr., Peng T, Strom BL, Van Den Eeden SK, Ehrlich SF, Habel LA: **Cohort study of pioglitazone and cancer incidence in patients with diabetes.** *Diabetes Care* 2011, **34**(4):923-929.
61. Grimaldi-Bensouda L, Cameron D Fau - Marty M, Marty M Fau - Barnett AH, Barnett Ah Fau - Penault-Llorca F, Penault-Llorca F Fau - Pollak M, Pollak M Fau - Charbonnel B, Charbonnel B Fau - Riddle M, Riddle M Fau - Mignot L, Mignot L Fau - Boivin J-F, Boivin Jf Fau - Khachatryan A *et al*: **Risk of breast cancer by individual insulin use: an international multicenter study.** (1935-5548 (Electronic)).
62. Gu YJ, Wang CF, Zheng Y, Hou XH, Mo YF, Yu WH, Zhang L, Hu C, Nan HR, Chen L *et al*: **Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai.** *Plos One* 2013, **8**(1).
63. Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, Ferrara A: **Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.** *Diabetes Care* 2013, **36**(12):3953-3960.
64. Home PD, Lagarenne P: **Combined randomised controlled trial experience of malignancies in studies using insulin glargine.** *Diabetologia* 2009, **52**(12):2499-2506.
65. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH: **The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.** *Exp Diabetes Res* 2012, **2012**:413782.
66. Koro C, Barrett S, Qizilbash N: **Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.** *Pharmacoepidemiol Drug Saf* 2007, **16**(5):485-492.

67. Kostev K: **Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin.** *Diabetologia* 2012, **55**(5):1554-1555.
68. Lind M, Fahlen M, Eliasson B, Oden A: **The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.** *Primary Care Diabetes* 2012, **6**(1):53-59.
69. Ljung R, Talback M Fau - Haglund B, Haglund B Fau - Jonasson JM, Jonasson Jm Fau - Gudbjornsdottir S, Gudbjornsdottir S Fau - Steineck G, Steineck G: **Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.** 2011(1651-226X (Electronic)).
70. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A *et al*: **Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.** *Diabetes Care* 2010, **33**(9):1997-2003.
71. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M: **Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.** *Diabetes Care* 2011, **34**(9):1965-1971.
72. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H: **Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.** *Diabetologia* 2012, **55**(7):1953-1962.
73. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA: **Type 2 diabetes mellitus, glycemic control, and cancer risk.** *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)* 2014, **23**(2):134-140.
74. Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM: **Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.** *Cancer Causes Control* 2012, **23**(11):1785-1795.
75. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, Johnston P, Davis M: **Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.** *Diabetologia* 2009, **52**(9):1971-1973.
76. Ruiten R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH: **Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.** *Diabetologia* 2012, **55**(1):51-62.
77. Sturmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, Macdonald E, Wang R, Lavange LM, Pate V *et al*: **Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.** *Diabetes Care* 2013, **36**(11):3517-3525.
78. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M: **Long-term effects of insulin glargine on the risk of breast cancer.** *Diabetologia* 2011, **54**(9):2254-2262.
79. Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S: **Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.** *Clinical drug investigation* 2013, **33**(9):621-631.
80. Jorgensen L, Dideriksen L, Drejer K: **CARCINOGENIC EFFECT OF THE HUMAN INSULIN ANALOG B10 ASP IN FEMALE RATS.** In: *Diabetologia: 1992*: SPRINGER VERLAG 175 FIFTH AVE, NEW YORK, NY 10010; 1992: A3-A3.
81. Sommerfeld MR, Muller G Fau - Tschank G, Tschank G Fau - Seipke G, Seipke G Fau - Habermann P, Habermann P Fau - Kurrle R, Kurrle R Fau - Tennagels N, Tennagels N: **In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.** (1932-6203 (Electronic)).
82. Kuerzel GU, Shukla U Fau - Scholtz HE, Scholtz He Fau - Pretorius SG, Pretorius Sg Fau - Wessels DH, Wessels Dh Fau - Venter C, Venter C Fau - Potgieter MA, Potgieter Ma Fau - Lang AM, Lang Am Fau - Koose T, Koose T Fau - Bernhardt E, Bernhardt E: **Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.** (0300-7995 (Print)).
83. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T, Becker RH: **Plasma exposure to insulin glargine and its metabolites m1 and m2 after subcutaneous injection of therapeutic and suprathreshold doses of glargine in subjects with type 1 diabetes.** *Diabetes Care* 2012, **35**(12):2626-2630.
84. Werner H, Chantelau EA: **Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.** (1758-5996 (Electronic)).
85. Van Oosterhout JP, Van der Laan Jw Fau - De Waal EJ, De Waal Ej Fau - Olejniczak K, Olejniczak K Fau - Hilgenfeld M, Hilgenfeld M Fau - Schmidt V, Schmidt V Fau - Bass R, Bass R: **The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe.** (0273-2300 (Print)).

86. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC *et al*: **Basal insulin and cardiovascular and other outcomes in dysglycemia.** *N Engl J Med* 2012, **367**(4):319-328.
87. Fleming ST, Rastogi A Fau - Dmitrienko A, Dmitrienko A Fau - Johnson KD, Johnson KD: **A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer.** (0025-7079 (Print)).
88. Hou G, Zhang S Fau - Zhang X, Zhang X Fau - Wang P, Wang P Fau - Hao X, Hao X Fau - Zhang J, Zhang J: **Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes.** (1573-7217 (Electronic)).
89. Liao S, Li J Fau - Wang L, Wang L Fau - Zhang Y, Zhang Y Fau - Wang C, Wang C Fau - Hu M, Hu M Fau - Ma B, Ma B Fau - Wang G, Wang G Fau - Sun S, Sun S: **Type 2 diabetes mellitus and characteristics of breast cancer in China.** (1513-7368 (Print)).
90. Luo J, Virnig B Fau - Hendryx M, Hendryx M Fau - Wen S, Wen S Fau - Chelebowski R, Chelebowski R Fau - Chen C, Chen C Fau - Rohan T, Rohan T Fau - Tinker L, Tinker L Fau - Wactawski-Wende J, Wactawski-Wende J Fau - Lessin L, Lessin L Fau - Margolis K *et al*: **Diabetes, diabetes treatment and breast cancer prognosis.** (1573-7217 (Electronic)).
91. Srokowski TP, Fang S Fau - Hortobagyi GN, Hortobagyi Gn Fau - Giordano SH, Giordano SH: **Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.** (1527-7755 (Electronic)).
92. van de Poll-Franse LV, Houterman S Fau - Janssen-Heijnen MLG, Janssen-Heijnen MI Fau - Dercksen MW, Dercksen Mw Fau - Coebergh JWW, Coebergh Jw Fau - Haak HR, Haak HR: **Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis.** (0020-7136 (Print)).
93. Besic N, Satej N: **Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma.** *BMC Res Notes* 2013, **6**:416.
94. Cleveland RJ, North Ke Fau - Stevens J, Stevens J Fau - Teitelbaum SL, Teitelbaum SI Fau - Neugut AI, Neugut Ai Fau - Gammon MD, Gammon MD: **The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project.** (1573-7225 (Electronic)).
95. Currie CJ, Poole Cd Fau - Jenkins-Jones S, Jenkins-Jones S Fau - Gale EAM, Gale Ea Fau - Johnson JA, Johnson Ja Fau - Morgan CL, Morgan CL: **Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.** (1935-5548 (Electronic)).
96. Erickson K, Patterson Re Fau - Flatt SW, Flatt Sw Fau - Natarajan L, Natarajan L Fau - Parker BA, Parker Ba Fau - Heath DD, Heath Dd Fau - Laughlin GA, Laughlin Ga Fau - Saquib N, Saquib N Fau - Rock CL, Rock Cl Fau - Pierce JP, Pierce JP: **Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer.** (1527-7755 (Electronic)).
97. Kaplan MA, Pekkolay Z Fau - Kucukoner M, Kucukoner M Fau - Inal A, Inal A Fau - Urakci Z, Urakci Z Fau - Ertugrul H, Ertugrul H Fau - Akdogan R, Akdogan R Fau - Firat U, Firat U Fau - Yildiz I, Yildiz I Fau - Isikdogan A, Isikdogan A: **Type 2 diabetes mellitus and prognosis in early stage breast cancer women.** (1559-131X (Electronic)).
98. Peairs KS, Barone Bb Fau - Snyder CF, Snyder Cf Fau - Yeh H-C, Yeh Hc Fau - Stein KB, Stein Kb Fau - Derr RL, Derr Ri Fau - Brancati FL, Brancati Fl Fau - Wolff AC, Wolff AC: **Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.** (1527-7755 (Electronic)).
99. Redaniel MT, Jeffreys M Fau - May MT, May Mt Fau - Ben-Shlomo Y, Ben-Shlomo Y Fau - Martin RM, Martin RM: **Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.** (1573-7225 (Electronic)).
100. Schrauder MG, Fasching Pa Fau - Haberle L, Haberle L Fau - Lux MP, Lux Mp Fau - Rauh C, Rauh C Fau - Hein A, Hein A Fau - Bayer CM, Bayer Cm Fau - Heusinger K, Heusinger K Fau - Hartmann A, Hartmann A Fau - Strehl JD, Strehl Jd Fau - Wachter DL *et al*: **Diabetes and prognosis in a breast cancer cohort.** (1432-1335 (Electronic)).
101. Yeh HC, Platz Ea Fau - Wang N-Y, Wang Ny Fau - Visvanathan K, Visvanathan K Fau - Helzlsouer KJ, Helzlsouer KJ Fau - Brancati FL, Brancati FL: **A prospective study of the associations between treated diabetes and cancer outcomes.** (1935-5548 (Electronic)).
102. Lipscombe LL, Goodwin Pj Fau - Zinman B, Zinman B Fau - McLaughlin JR, McLaughlin Jr Fau - Hux JE, Hux JE: **The impact of diabetes on survival following breast cancer.** (0167-6806 (Print)).
103. Liu X, Ji J Fau - Sundquist K, Sundquist K Fau - Sundquist J, Sundquist J Fau - Hemminki K, Hemminki K: **The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden.** (1097-0142 (Electronic)).

104. Currie CJ, Poole Cd Fau - Evans M, Evans M Fau - Peters JR, Peters Jr Fau - Morgan CL, Morgan CL: **Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.** (1945-7197 (Electronic)).
105. Ioacaru S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M: **Cancer specific mortality in insulin-treated type 2 diabetes patients.** *PLoS ONE* 2014, **9**(3).
106. Rose DP, Vona-Davis L: **The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.** (1479-6821 (Electronic)).
107. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L *et al*: **Monomeric insulins obtained by protein engineering and their medical implications.** *Nature* 1988, **333**(6174):679-682.
108. Dideriksen LH JL, Drejer K: **Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp.** *Diabetes* 1992, **41**(143A).
109. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sorensen R, Lindhardsen J, Gislason GH, Kober L, Torp-Pedersen C: **Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people.** *BMJ Open* 2012, **2**(3).
110. Eckardt K, May C, Koenen M, Eckel J: **IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.** *Diabetologia* 2007, **50**(12):2534-2543.
111. Chisalita SI, Arnqvist HJ: **Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.** *Am J Physiol Endocrinol Metab* 2004, **286**(6):E896-901.
112. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L, Striffler BA, Li S, Shang J, Beals JM *et al*: **pi-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.** *Peptides* 2007, **28**(4):935-948.
113. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T: **Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.** *Diabetes* 2000, **49**(6):999-1005.
114. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N: **In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.** *PLoS One* 2010, **5**(3):e9540.
115. Warnken M, Reitzenstein U, Sommer A, Fuhrmann M, Mayer P, Enzmann H, Juergens UR, Racke K: **Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts.** *Naunyn Schmiedebergs Arch Pharmacol* 2010, **382**(5-6):511-524.
116. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H: **Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.** *Diabetes Metab Res Rev* 2009, **25**(1):41-49.
117. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H: **Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.** *Diabetologia* 2010, **53**(12):2667-2675.
118. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M: **Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells.** *Horm Metab Res* 2007, **39**(1):65-67.
119. Bahr M, Kolter T, Seipke G, Eckel J: **Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells.** *Eur J Pharmacol* 1997, **320**(2-3):259-265.
120. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR: **Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.** *J Clin Endocrinol Metab* 2001, **86**(12):5838-5847.
121. Liefvendahl E, Arnqvist HJ: **Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.** *Horm Metab Res* 2008, **40**(6):369-374.
122. Muller K, Weidinger C, Fuhrer D: **Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells.** *Diabetologia* 2010, **53**(5):1001-1003.
123. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T: **Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.** *Diabetes Res Clin Pract* 2008, **81**(3):269-277.
124. Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, Nawroth PP, Ritzel RA: **Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine.** *Diabetes Care* 2008, **31**(6):1105-1111.

125. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U: **High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.** *Diabetes Res Clin Pract* 2011, **91**(2):177-182.
126. Liu SY, Liang Y, Lin TX, Su F, Liang WW, Uwe H, Li Y: **MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.** *Chin Med J (Engl)* 2012, **125**(23):4197-4201.
127. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: **Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.** *Diabetologia* 2010, **53**(8):1743-1753.
128. Swift S, Lorens J, Achacoso P, Nolan GP: **Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems.** *Curr Protoc Immunol* 2001, **Chapter 10**:Unit 10 17C.
129. Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B: **Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.** *Breast Cancer Res* 2011, **13**(3):R52.
130. Vichai V, Kirtikara K: **Sulforhodamine B colorimetric assay for cytotoxicity screening.** *Nat Protoc* 2006, **1**(3):1112-1116.
131. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R: **Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay.** *Diabetes Metab* 2007, **33**(3):205-212.
132. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W: **Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes.** *Anal Chem* 2005, **77**(11):3579-3585.
133. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Kostler WJ *et al*: **Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.** *Endocr Relat Cancer* 2007, **14**(4):1053-1062.
134. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A: **A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.** *J Clin Endocrinol Metab* 2002, **87**(1):245-254.
135. Belfiore A, Malaguarnera R: **Insulin receptor and cancer.** *Endocr Relat Cancer* 2011, **18**(4):R125-147.
136. Pollak M: **The insulin and insulin-like growth factor receptor family in neoplasia: an update.** *Nat Rev Cancer* 2012, **12**(3):159-169.
137. Owens DR, Bolli GB: **Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.** *Diabetes Technol Ther* 2008, **10**(5):333-349.
138. Duckworth WC, Bennett RG, Hamel FG: **Insulin degradation: progress and potential.** *Endocr Rev* 1998, **19**(5):608-624.
139. Fawcett J, Tsui BT, Krueger MC, Duckworth WC: **Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism.** *Metabolism* 2004, **53**(8):1037-1044.
140. Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P, Hahn A, Schmidt R, Bolli GB, Fanelli CG: **Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.** *Diabetes Care* 2012, **35**(12):2647-2649.
141. Varewijck AJ, Yki-Jarvinen H, Schmidt R, Tennagels N, Janssen JA: **Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling.** *Diabetes* 2013.
142. Shi Y, Hu FB: **The global implications of diabetes and cancer.** *Lancet* 2014, **383**(9933):1947-1948.
143. Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G: **Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.** *Acta Oncol* 2011, **50**(5):685-693.
144. Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, Ferrara A: **Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.** *Diabetes Care* 2013, **36**(12):3953-3960.
145. Rostoker R, Bitton-Worms K, Caspi A, Shen-Orr Z, LeRoith D: **Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.** *Endocrinology* 2013, **154**(5):1701-1710.
146. Bordeleau L, Gerstein HC: **Response to Zanders et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.** *Diabetes Care* 2014;**37**:1360-1366. *Diabetes Care* 2014, **37**(10):e223.
147. Hansen BF: **Insulin analogues with increased mitogenic potency--are they safe?** *Horm Metab Res* 2008, **40**(6):431-433.

148. Pollak M: **Insulin and insulin-like growth factor signalling in neoplasia.** *Nat Rev Cancer* 2008, **8**(12):915-928.
149. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG: **Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.** *Biochem J* 1996, **315** (Pt 1):271-279.
150. Romer M, Eichner J, Metzger U, Templin MF, Plummer S, Ellinger-Ziegelbauer H, Zell A: **Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat.** *PLoS One* 2014, **9**(5):e97640.
151. Melis JP, Derks KW, Pronk TE, Wackers P, Schaap MM, Zwart E, van Ijcken WF, Jonker MJ, Breit TM, Pothof J *et al*: **In vivo murine hepatic microRNA and mRNA expression signatures predicting the (non-)genotoxic carcinogenic potential of chemicals.** *Arch Toxicol* 2014, **88**(4):1023-1034.
152. Huijts PE, van Dongen M, de Goeij MC, van Moolenbroek AJ, Blanken F, Vreeswijk MP, de Kruijf EM, Mesker WE, van Zwet EW, Tollenaar RA *et al*: **Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.** *Breast Cancer Res* 2011, **13**(4):R72.
153. Ter Braak B, Siezen C, Speksnijder EN, Koedoot E, van Steeg H, Salvatori DC, van de Water B, van der Laan JW: **Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53(R270H/+)WAPCre mouse model.** *Breast Cancer Res* 2015, **17**(1):518.
154. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: **Exploration, normalization, and summaries of high density oligonucleotide array probe level data.** *Biostatistics (Oxford, England)* 2003, **4**(2):249-264.
155. Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS: **Assessing gene significance from cDNA microarray expression data via mixed models.** *Journal of computational biology : a journal of computational molecular cell biology* 2001, **8**(6):625-637.
156. Hochberg Y, Benjamini Y: **More powerful procedures for multiple significance testing.** *Statistics in medicine* 1990, **9**(7):811-818.
157. Smyth GK, Michaud J, Scott HS: **Use of within-array replicate spots for assessing differential expression in microarray experiments.** *Bioinformatics (Oxford, England)* 2005, **21**(9):2067-2075.
158. Clark AR, Toker A: **Signalling specificity in the Akt pathway in breast cancer.** *Biochemical Society transactions* 2014, **42**(5):1349-1355.
159. Myung DS, Park YL, Kim N, Chung CY, Park HC, Kim JS, Cho SB, Lee WS, Lee JH, Joo YE: **Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis.** *Oncology reports* 2014, **31**(2):788-794.
160. Chandra A, Lan S, Zhu J, Siclari VA, Qin L: **Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression.** *The Journal of biological chemistry* 2013, **288**(28):20488-20498.
161. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H: **Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic factor.** *Endocr Relat Cancer* 2007, **14**(2):279-292.
162. Matsuo T, Dat Ie T, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T: **Early Growth Response 4 Is Involved in Cell Proliferation of Small Cell Lung Cancer through Transcriptional Activation of Its Downstream Genes.** *PLoS One* 2014, **9**(11):e113606.
163. Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Mareel M, Bracke M, Salmon I, De Wever O, Demetter P: **Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer.** *Br J Cancer* 2013, **109**(1):114-120.
164. Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J *et al*: **PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis.** *Cancer Res* 2011, **71**(10):3709-3719.
165. Uekusa S, Kawashima H, Sugito K, Yoshizawa S, Shinjima Y, Igarashi J, Ghosh S, Wang X, Fujiwara K, Ikeda T *et al*: **Nr4a3, a possible oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon.** *Int J Oncol* 2014, **44**(5):1669-1677.
166. Wells JE, Howlett M, Cole CH, Kees UR: **Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer.** *Int J Cancer* 2014.
167. Bechara EG, Sebestyen E, Bernardis I, Eyrae E, Valcarcel J: **RBMS5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation.** *Molecular cell* 2013, **52**(5):720-733.
168. Yousefzadeh MJ, Wyatt DW, Takata K, Mu Y, Hensley SC, Tomida J, Bylund GO, Doublet S, Johansson E, Ramsden DA *et al*: **Mechanism of suppression of chromosomal instability by DNA polymerase POLQ.** *PLoS genetics* 2014, **10**(10):e1004654.

169. Tennagels N, Werner U: **The metabolic and mitogenic properties of basal insulin analogues.** *Arch Physiol Biochem* 2013, **119**(1):1-14.
170. Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ: **Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.** *Breast Cancer Res Treat* 2011, **128**(1):243-250.
171. Arnaldez FI, Helman LJ: **Targeting the insulin growth factor receptor 1.** *Hematol Oncol Clin North Am* 2012, **26**(3):527-542, vii-viii.
172. Kellerer M, Haring HU: **Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties.** *Exp Clin Endocrinol Diabetes* 2001, **109**(1):63-64.
173. Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, Werner U: **Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats.** *Diabetologia* 2013.
174. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubaue H, Troschau G: **Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.** *Int J Toxicol* 2002, **21**(3):171-179.
175. Stammberger I, Essermeant L: **Insulin glargine: a reevaluation of rodent carcinogenicity findings.** *Int J Toxicol* 2012, **31**(2):137-142.
176. Nagel JM, Staffa J, Renner-Muller I, Horst D, Vogeser M, Langkamp M, Hoeflich A, Goke B, Kolligs FT, Mantzoros CS: **Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.** *Horm Cancer* 2010, **1**(6):320-330.
177. Buchs AE, Silverman BG: **Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study.** *Metabolism* 2011, **60**(10):1379-1385.
178. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H: **Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.** *Diabetes Care* 2013, **36**(2):294-301.
179. van Staa TP, Patel D, Gallagher AM, de Bruin ML: **Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.** *Diabetologia* 2012, **55**(3):654-665.
180. Scheer N, Snaith M, Wolf CR, Seibler J: **Generation and utility of genetically humanized mouse models.** *Drug Discov Today* 2013, **18**(23-24):1200-1211.
181. Frese KK, Tuveson DA: **Maximizing mouse cancer models.** *Nat Rev Cancer* 2007, **7**(9):645-658.
182. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T *et al*: **Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.** *Cancer Res* 2005, **65**(18):8166-8173.
183. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, van Oostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T *et al*: **Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage.** *Cancer Res* 2007, **67**(10):4648-4656.
184. Derksen PW, Braumuller TM, van der Burg E, Hornsveld M, Mesman E, Wesseling J, Krimpenfort P, Jonkers J: **Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.** *Dis Model Mech* 2011, **4**(3):347-358.
185. Chignola R, Foroni RI: **Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology.** *IEEE Trans Biomed Eng* 2005, **52**(5):808-815.
186. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM *et al*: **The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.** *Oncogene* 2000, **19**(8):968-988.
187. Cardiff RD: **The pathology of EMT in mouse mammary tumorigenesis.** *J Mammary Gland Biol Neoplasia* 2010, **15**(2):225-233.
188. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD: **Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas.** *Vet Pathol* 2009, **46**(4):736-745.
189. Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, Fels JJ, Fledelius C, Hansen BF, Pollak M: **Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts.** *PLoS One* 2013, **8**(11):e79710.
190. Klarenbeek S, van Miltenburg MH, Jonkers J: **Genetically engineered mouse models of PI3K signaling in breast cancer.** *Mol Oncol* 2013, **7**(2):146-164.
191. Varewijck AJ, Janssen JA: **Insulin and its analogs and their affinities to the IGF-1 receptor.** *Endocr Relat Cancer* 2012.

192. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS: **Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.** *PLoS One* 2011, **6**(6):e21368.
193. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R: **Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.** *Journal of cellular physiology* 2014, **229**(11):1817-1821.
194. Ter Braak B SC, Speksnijder EN, Koedoot E, Van Steeg H, Salvatori DCF, Van de Water B and Van der Laan JW: **Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model.** *Breast Cancer Res* 2015.
195. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T: **Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.** *Cell* 2004, **119**(6):847-860.
196. Torsoli A: **Sanofi Accelerates Development of New Lantus Formulation.** In.: bloomberg; 2011.
197. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**(5):646-674.
198. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW: **Cancer genome landscapes.** *Science* 2013, **339**(6127):1546-1558.
199. Yizhak K, Le Devedec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, Schulze A, van de Water B, Ruppin E: **A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration.** *Molecular systems biology* 2014, **10**:744.
200. Chang C-C, Lin C-J: **LIBSVM: A library for support vector machines.** *ACM Trans Intell Syst Technol* 2011, **2**(3):1-27.
201. Zur H, Ruppin E, Shlomi T: **iMAT: an integrative metabolic analysis tool.** *Bioinformatics (Oxford, England)* 2010, **26**(24):3140-3142.
202. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO: **Global reconstruction of the human metabolic network based on genomic and bibliomic data.** *Proc Natl Acad Sci U S A* 2007, **104**(6):1777-1782.
203. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL: **Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.** *Mol Cancer* 2011, **10**:40.
204. Bae WK, Hennighausen L: **Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.** *Mol Cell Endocrinol* 2014, **382**(1):593-597.
205. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN *et al*: **Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells.** *Oncogene* 2014, **33**(4):440-448.
206. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R: **Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.** *Mol Cell Biol* 1999, **19**(5):3278-3288.
207. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, Tennagels N, Werner U, Leroith D: **Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-1 receptor.** *Diabetes* 2013.
208. Golpour M, Akhavan Niaki H, Khorasani HR, Hajian A, Mehrasa R, Mostafazadeh A: **Human fibroblast switches to anaerobic metabolic pathway in response to serum starvation: a mimic of warburg effect.** *International journal of molecular and cellular medicine* 2014, **3**(2):74-80.
209. Rader RA: **(Re)defining biopharmaceutical.** *Nature biotechnology* 2008, **26**(7):743-751.
210. ICHS1A: **Guideline on the need for carcinogenicity studies of Pharmaceuticals.** In.; 1995.
211. Sciacca L, Le Moli R, Vigneri R: **Insulin analogs and cancer.** *Front Endocrinol (Lausanne)* 2012, **3**:21.
212. Lind M, Fahlen M, Eliasson B, Oden A: **The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.** *Prim Care Diabetes* 2012, **6**(1):53-59.
213. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R: **Diabetes and cancer.** *Endocr Relat Cancer* 2009, **16**(4):1103-1123.
214. Hanahan D, Weinberg RA: **The hallmarks of cancer.** *Cell* 2000, **100**(1):57-70.
215. van Miltenburg MH, Jonkers J: **Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.** *Current opinion in genetics & development* 2012, **22**(1):21-27.
216. Yin M, Zhou J, Gorak EJ, Quddus F: **Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.** *Oncologist* 2013, **18**(12):1248-1255.

